Clinical Trial: Trastuzumab rezetecan induction followed by dalpiciclib plus endocrine maintenance as first-line therapy in HR+/HER2-low advanced breast cancer: a phase II exploratory trial (China)

Posted On: 2026-11-10

China, Nov. 10 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Trastuzumab rezetecan induction followed by dalpiciclib plus endocrine maintenance as first-line therapy in HR+/HER2-low advanced breast cancer: a phase II exploratory trial'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600136193

Registration Time: 2026/11/06

Type: Interventional study

Primary Sponsor: Harbin Medical University Cancer Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=351508

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया हमे संपर्क करें.

विशेष

Category

Source

Publication

Location

Clinical Trial: Trastuzumab rezetecan induction followed by dalpiciclib plus endocrine maintenance as first-line therapy in HR+/HER2-low advanced breast cancer: a phase II exploratory trial (China)